99 mTechnetium methylene diphosphonate ( 99 mTc MDP) bone scintigraphy is currently the method of choice for the detection of bone metastases, but 18 Ffluoro-deoxy-D-glucose positron emission tomography (i 8 FDG PET) offers superior spatial resolution and improved sensitivity. We have compared '8FDG PET with 99mTc MDP bone scintigraphy in patients with skeletal metastases from breast cancer and have analyzed the data in subgroups based on radiographic characteristics of lesions. BREAST CANCER is common; women in the United Kingdom have a lifetime probability of 1 in 12 to develop this disease. In the UK population, the annual incidence is 25,000 new cases, but the prevalence is estimated at 105,000.1 The skeleton is the most common distant site to which breast cancer spreads. Bone metastases affect 8% of all patients who develop breast cancer, but this increases to 70% in those with advanced disease. Secondary tumors in bone cause much of the morbidity and disability of this disease because of the potentially prolonged clinical course (median survival of 24 months for those in whom disease remains confined to the skeleton).
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BREAST CANCER is common; women in the United Kingdom have a lifetime probability of 1 in 12 to develop this disease. In the UK population, the annual incidence is 25,000 new cases, but the prevalence is estimated at 105,000.1 The skeleton is the most common distant site to which breast cancer spreads. Bone metastases affect 8% of all patients who develop breast cancer, but this increases to 70% in those with advanced disease. Secondary tumors in bone cause much of the morbidity and disability of this disease because of the potentially prolonged clinical course (median survival of 24 months for those in whom disease remains confined to the skeleton). 2 Complications include pain, pathologic fracture, hypercalcemia, myelosuppression, spinal cord compression, and nerve root lesions, and 20% of the patients remain alive at 5 years. The costs of treating bone metastases and associated complications make a major demand on health care resources. 3 Skeletal damage results from increased bone resorption caused by stimulation of osteoclasts by tumor-derived humoral mediators that include growth factors and cytokines. 4 It is the central role of increased osteoclast activation in skeletal metastases that has led to the development of newer treatments, such as the bisphosphonates that inhibit osteoclast activity and reduce skeletal morbidity. 5 Techniques are required that may help identify at an earlier stage those patients who may benefit most from these interventions. Deoxyglucose, an analogue of glucose, is labeled with the Results:
FDG PET detected more lesions than 99mTc MDP scintigraphy (mean, 14.1 and 7.8 lesions, respectively; P < .01). However, 18 FDG detected fewer bone metastases compared with 99mTc MDP scintigraphy in a subgroup of patients with osteoblastic disease (P < .05). Higher SUVs were observed for osteolytic than osteoblastic disease (mean, 6.77 and 0.95, respectively; P < .01). Survival was lower in patients with osteolytic disease compared with the remainder (P = .01). A difference in survival was not found for those patients with high SUVs (> 3.6; P = .4).
Conclusion:
18 FDG PET is superior to bone scintigraphy in the detection of osteolytic breast cancer metastases, which led to a poorer prognosis. In contrast, osteoblastic metastases show lower metabolic activity and are frequently undetectable by PET. The biologic explanation for this observation remains to be elucidated. 6 with the ability to detect small volumes of disease before morphologic changes appear. In addition, the degree of uptake has been correlated with prognosis and grade of malignancy in some tumors, which includes breast cancer. 7 We studied 23 women with both osteolytic and osteoblastic metastases from carcinoma of the breast with 18FDG PET to correlate findings with radiologic appearances and to assess the sensitivity of this technique in the detection of osseous metastases compared with 99mTc MDP bone scintigraphy.
PATIENTS AND METHODS
Twenty-three women (mean age, 52 years; range, 29 to 70 years) with a history of breast cancer who had been referred for bone scintigraphy that showed evidence of bone metastases were included. All patients had at least one other method of confirmation that bone scan findings were caused by metastatic disease, which included plain film radiography (n = 17), computed tomography (CT; n = 10), magnetic resonance imaging (n = 6), or bone biopsy (n = 2). Patients were categorized with lytic, sclerotic, or mixed metastatic bone disease by two independent observers at the original diagnosis of bone metastases from either original plain films (n = 16) or CT scans (n = 4) that were performed before subsequent systemic treatment had been started. Three patients remained unclassifiable because bone metastases were only visible with bone scintigraphy and magnetic resonance imaging.
Twenty-one of the 23 women had evidence of progressive metastatic disease during the study period. Two patients had stable disease and were currently not receiving specific anticancer treatment; both had stopped hormone manipulation treatment 5 and 12 months previously without a documented response to therapy.
Ten patients received hormone manipulation therapy, which ended between I and 48 months (mean, 18.2 months) before PET scanning, and three patients were currently receiving this treatment, but all 13 patients had progressive disease despite this. Five patients had previously received chemotherapy between 7 and 13 months (mean. 10.3 months) and four patients had previously received treatment with bisphosphonates between I and 84 months (mean, 34.5 months) before PET scans. Two patients had received prior palliative radiotherapy to bone metastases.
Imaging
In all but one patient, 9smTc MDP bone scans and 1'FDG PET scans were performed within 8 weeks of each other (mean. 2.9 weeks). One patient was included in whom the bone scan appearances had not changed from 9 months before to 5 months after the PET scan.
Patients fasted for 6 hours before the PET scan. Half-body (above the knees to midbrain) emission and localized emission/transmission scans were performed 1 hour after the injection of 350 MBq of 18FDG. Sixteen patients had both half-body emission and localized emission/ transmission scans; the remainder had localized scans only. Standardized uptake values (SUVs) were calculated from attenuation-corrected data for bone lesions within the localized field of view and were corrected for partial volume effects. SUV = (activity in region of interest [ROI]/volume of ROI)/(injected activity/weight of patient)). For those patients with more than one lesion within the attenuationcorrected, localized views, the mean SUV for identified lesions was used. The included lesions had remained radiographically stable in type from pretreatment classification to the time of the study.
Bone scans were performed after the injection of 550 MBq of " mTc MDP that used high-resolution collimation on a twin-headed gamma camera. Metastatic bone scan and PET bone lesions were counted at different sittings by an observer blinded to all patient details.
Survival curves 12 were plotted that compared survival in groups with sclerotic, mixed, and lytic disease and in two groups separated by a median SUV value of 3.6.
RESULTS
All patients had bone scan evidence of metastatic disease confirmed by at least one other imaging technique or, in two patients, by bone biopsy. Of the 16 patients who had half-body PET scans, between I and 38 (mean, 7.8) 9 9mTc MDP bone scan lesions were identified. The corresponding results for these 16 patients with 1 'FDG PET were between 0 and 61 (mean, 14.1) bone lesions (P < .01, Wilcoxon's signed rank-sum test).
Twenty patients had radiologically classifiable disease. Of these, six patients had sclerotic disease, five patients had mixed disease, and nine patients had lytic disease. The mean SUVs for these groups were 0.95, 3.64, and 6.77, respectively ( Table 1 ; P < .01, Kruskal Wallis test).
Of the 16 patients who had half-body PET scans, three patients had sclerotic disease, three patients had mixed disease, eight patients had lytic disease, and two patients were not classified. In two of three patients with sclerotic disease, J8FDG PET showed fewer lesions than 9 9mTc MDP bone scan in contrast to those with lytic disease, in whom no patients had fewer and seven of eight patients had more lesions identified with 1SFDG PET. Overall, 18FDG PET detected fewer lesions than bone scans in the subgroup with osteoblastic disease compared with those with purely lytic disease (P < .05, Wilcoxon's signed rank-sum test).
Survival Data
When survival curves are plotted for sclerotic, mixed, and lytic disease from the time of diagnosis of bone metastases, a significant difference is found in survival between each group (P = .04, X2), and if patients with lytic disease are compared with patients with sclerotic and mixed disease as a combined group, a more significant difference in survival is found (P = .01, X 2 ; Fig 1) . When length of survival from the diagnosis of bone metastases in those patients with an SUV greater than the median (3.6) is compared with p an SUV less than the median, a difference in su found (P = .40, X 2 ).
DISCUSSION
A difference in the avidity of accumulation o been found between sclerotic, mixed, and lytic higher SUVs.
The reason for greater avidity for FDG in lytic metastases is unknown, but may reflect a higher glycolytic rate in this type of metastasis. Sclerotic metastases are relatively acellular, however, 13 and as such, lower volumes of viable tumor tissue within individual lesions may influence the degree of uptake of 1 8 FDG. In addition, more aggressive, lytic disease might be expected to outstrip its blood supply, which renders the tumor relatively hypoxic compared with sclerotic disease. Hypoxia increases FDG uptake in some cell lines, of 23 patients) had progressive disease at the time of the study.
There are a number of reasons why I 5 FDG PET may show an increase in sensitivity for the detection of osseous metastases compared with 99mTc MDP bone scintigraphy. PET is a method that intrinsically has a higher spatial resolution than gamma camera imaging and also routinely includes tomography. Tomography was not performed in this study on 99 "Tc MDP bone scans. In addition, '8FDG PET and bone scintigraphy exploit different mechanisms to detect tumor involvement. 99mTc MDP bone scintigraphy relies on an osteoblastic bone response to tumor, whereas ' 8 FDG PET measures glucose uptake into the tumor itself.
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FDG PET is therefore more likely to detect metastases at an early stage, perhaps when they are confined to bone marrow.
A correlation of FDG uptake into soft tissue metastases from breast carcinoma has previously been shown with tumor grade and prognosis,7,8 but this study has not shown a difference in survival dependent on SUV measurement.
There is no obvious explanation for the difference in behavior of osteoblastic and osteolytic metastases, but the actions of growth factors on both tumor growth and bone metabolism may also be involved. A variety of growth factors, which includes transforming growth factors (TGFs), appear to regulate breast cancer cell growth." 1 These same factors are known to regulate bone remodeling. For example, TGF-ot and related peptides stimulate the growth of human breast cancer cells. TGF-e is also a potent stimulator of osteoclastic bone resorption.' 6 Conversely, TGF-P and related peptides are a family of inhibitory growth factors found in normal breast epithelium. TGF-P inhibits breast cancer cell growth and is induced by tamoxifen.' 7 TGF-3 is an inhibitor of osteoclastic bone resorption that stimulates osteoblasts to form new bone 1 " 19 and many of the events involved in bone formation, which include chemotaxis of osteoblast precursors, mitogenesis of osteoblast precursors, and differentiated function in committed osteoblasts.
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It is possible that those patients who develop an osteoblastic response (sclerotic metastases) induced in part by TGF-P, which in turn has an inhibitory effect on tumor cells, may show improved survival and lower accumulation of 18FDG compared with those with lytic metastases.
Irrespective of the underlying molecular mechanisms,
I8FDG
PET detects more bone lesions than 99mTc MDP bone scintigraphy in patients with osteolytic metastases. These patients experience the most skeletal morbidity and have a reduced survival. Earlier detection of those patients who have a more aggressive clinical course and poorer survival may help identify a group who could benefit from the early introduction of newer systemic treatments, such as the bisphosphonates.
